All lobbying filings

THE MCMANUS GROUP

Lobbying for GENENTECH

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

JOHN MCMANUS

Previously held: Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 3

Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

Taxation/Internal Revenue Code

Issues related to tax exempt hospitals and charity care.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.